1 / 25

Sepsis: An Update on Pathophysiology and Treatment Approaches

Sepsis: An Update on Pathophysiology and Treatment Approaches. Case Studies: An Overview. Learning objectives. Review real cases to understand when to use activated Protein C Note important differences between cases that influence decision to use or not use aPC

Rita
Download Presentation

Sepsis: An Update on Pathophysiology and Treatment Approaches

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sepsis: An Update on Pathophysiology and Treatment Approaches Case Studies: An Overview

  2. Learning objectives • Review real cases to understand when to use activated Protein C • Note important differences between cases that influence decision to use or not use aPC • Discuss “red flags” for particular patients that could make you nervous about using aPC

  3. Starting from common ground… • Appropriate supportive care • ABCs • Fluids • Vasopressors/inotropes • Organ support (ventilation, dialysis, etc.) • Appropriate empiric and adjusted antibiotics • Source control • Avoiding delays in diagnosing severe sepsis/septic shock, providing supportive care

  4. Case #1 • 26 year old female • Past history of seizure disorder, on phenytoin • Presents with 12 hour history of fever/chills/rigors, lower abdominal pain, no dysuria, no cough • 39.4 degrees C • HR 125, BP 75/40 --> 90/50 after 2L NS • No CV angle tenderness • No other obvious source • Urinalysis • 5-20 WBC/hpf • Bacteria seen

  5. Investigations • Laboratory: • WBC 1.0, 22% bands, Hb normal, plts normal • LFT’s normal, lytes, amylase normal • Creat 139 • Radiology: • CXR clear • CT (contrast) chest & abdomen: free fluid pelvis, edematous left kidney

  6. Case: Deterioration • Started on empiric antibiotics following cultures • (Cefotaxime, Cipro, Ampicillin, Flagyl) • 12hrs later: • HR to 180, BP 65/P despite ++ fluids • Shortness of breath, RR 40+ • Hypoxemia, bilateral pulmonary infiltrates • 7.23/PCO2 33/pO2 100/bic 14 on 80% O2 • Metabolic acidosis, lactate 2.6 • Increased transaminases, decreased urine output • Increased INR to 2.4

  7. Case • Intubated, mechanical ventilation, central venous catheter, arterial catheter, vasopressor • Blood cultures: Gram negative bacillus 2/2 bottles • PA catheter • Cardiac index 2.5L/min/m2 • PCWP 17 • Expected mortality now >40% • Septic Shock, ARDS

  8. Source Control in Sepsis • Localize and treat site of infection • Undrained pockets are lethal • Reviewed details of anticonvulsant therapy • Agent known to contribute to renal stones! • Repeat CT -> non-contrasted: left ureteric stone • To OR for basket extraction • Not possible -> stent placed

  9. Questions about the case… • Appropriate supportive care (including antibiotics)? • Timely source control? • Candidate for activated Protein C?

  10. Case: Activated Protein C • Infusion of activated Protein C started 24 hours after admission to ICU • INR 2.4 -> 2.0 prior to aPC, 1.3 on infusion • Infusion x 96 hours total • 12 hour window for OR (stent placed) • Stabilized clinically, inotropes weaned • Extubated day 7 • Discharged for urologic followup

  11. Lessons from Case 1 • Case history • 26-year-old female presents to ER • Diagnosed with severe Gram-negative sepsis with multisystem failure, septic shock, and ARDS • Undergoes surgery to remove kidney stone • Drotrecogin alfa (activated) infusion • Significance of case • Condition initially unrecognized, resolved with treatment for underlying condition

  12. Case #2 • 73-year-old male, retired • Heavy smoker of 2 packs/day until five years ago • Presented with increased shortness of breath, yellowish sputum production over the last week and slight fever at 38.3°C two days prior to admission • Chronic bronchitis on Ventolin®, Atrovent® • Last FEV1 in 1999 was 0.8 L/min • Pneumococcal pneumonia with severe sepsis, ICU admission and mechanical ventilation in 1996 — yearly vaccinations since

  13. Present history: • Dark urine and hasn’t voided in last 8 hours • Has used Ventolin® inhaler 4 times in last couple of hours

  14. Physical examination: • 23:00 • On admission, 80 kg • Laboured breathing at 35/min, prolonged expiratory time, accessory muscle use • Temperature 38.2°C • Distended internal jugulars, tachycardia at 110/min NSR, BP 90/50

  15. Physical examination (cont’d): • Positive HJ reflux • Fine crackles at both lung bases, swollen ankles • Right sided carotid bruit • Rest unremarkable

  16. Outstanding lab results: Na+ = 148 K+ = 3.2 BUN Urea = 15 PO2 = 130 Hg = 156 Hct = .47 Plat = 175 000 WBC = 12 500 no bands ABG = 7.27/56/26/55 room air Investigations:

  17. Investigations (cont’d): • CXR: hyperfiltration, suspect bronchiectasis both lung bases and doubtful left LL infiltrate • aPTT = 35/INR 1.3 • Lactates normal • ECG right axis deviation, negative T waves V1-V4 anterior leads

  18. Treatment, management and rationale: • 23:40 • BiPAP started in ER 12/5, 40% PIO2 • Solumedrol 40 mg IV q 6 hours, cefuroxime 1 gm IV q 8 hours and ICU consult • 500 mL Pentaspan given over 1 hour after bladder catheter revealed 20 cc of dark yellow urine with absence of blood on strip reagent

  19. Is this SIRS, sepsis, severe sepsis, or septic shock? • Is this patient a candidate for aPC?

  20. Treatment, management and rationale (cont’d): • D5NaCl 0.9% + KCl 40 mg/L at 80 cc/hour • Not at risk for bleeding • Not a candidate for rhAPC

  21. Lessons from Case 2 • Recognize non-specific nature of SIRS criteria • Alternative causes for hypotension, oliguria • Need for appropriate search for presumed or proven infection (COPD exacerbation doesn’t count)

  22. Case 2: COPDJean-Gilles Guimond, MD • Case history • 73-year-old male presents to ER with COPD/acute tracheobronchitis, ?pneumonia • Case highlights • Patient not a candidate for drotrecogin alfa (activated) therapy because suffering from COPD exacerbation not sepsis • Significance of case • Patient follows SIRS criteria but does not have sepsis • Patient recovers; not treated with drotrecogin alfa (activated)

  23. Case 3: Pneumococcal pneumoniaBruce Light, MD • Case history • 26-year-old woman, alcoholic, drug user • Taken to emergency by friends; in confused state, bad cough with yellow, bloody sputum, febrile • Obvious right lower lobe pneumonia on chest x-ray • Case highlights • Diagnosis: acute pneumococcal pneumonia with hypoxemic respiratory failure, septic shock requiring vasopressor infusion, acute renal insufficiency, and mild coagulopathy • Treated with drotrecogin alfa (activated) • Patient transferred to rehabilitation ward after 4 weeks • Significance of case • “Typical” scenario

  24. Case 4: Post-op infectionClaudio Martin, MD • Case history • 67-year-old male undergoes coronary artery bypass surgery 3 weeks prior to presentation • Re-admitted 3-weeks post-surgery for management of sternal dehiscence associated with infection • Develops respiratory distress; requires intubation and admitted to ICU • Started on drotrecogin alfa (activated) • Requires chest tube for large pleural effusion (?infected) • Drops Hb by 30 in 12 hours • Recovers • Significance of case • When to discontinue treatment transiently vs permanently

  25. Case 5: AML, febrile neutropeniaTom Stewart, MD • Case history • Patient with AML, pancytopenic with severe neutropenia and suspected lung infection • Case highlights • Patient excluded from PROWESS study due to low platelet count (15 000/mm3). Family approach physician about possible treatment with drotrecogin alfa (activated) • Case taken to clinical management team. Objections from oncologist (effect on leukemia and risk of bleeding) and pharmacist (cost and concern about use outside of guidelines) • Drotrecogin alfa (activated) not given; patient dies • Significance of case • Example of scenario where drotrecogin alfa not used

More Related